Clinical Trials Logo

Advanced Colorectal Cancer clinical trials

View clinical trials related to Advanced Colorectal Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03311750 Terminated - Clinical trials for Advanced Colorectal Cancer

Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer

A-REPEAT
Start date: March 26, 2018
Phase: Phase 2
Study type: Interventional

A-REPEAT (Anti-Epidermal Growth Factor Receptor -EGFR- rechallenge and plasma genotyping of patients with advanced colorectal tumors) is a Greek, investigator-initiated, single arm open-label phase II study of anti-EGFR therapy rechallenge in combination with chemotherapy in patients with advanced colorectal cancer. Patients with a metastatic, histologically proven colorectal carcinoma RAS wild type will be treated with a combination of panitumumab and third-line irinotecan-based or oxaliplatin-based chemotherapy (FOLFOX,FOLFIRI or irinotecan monotherapy).

NCT ID: NCT01271166 Terminated - Clinical trials for Advanced Colorectal Cancer

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Start date: October 2007
Phase: Phase 1
Study type: Interventional

This is a Phase I, dose finding, multicentre study evaluating the maximal tolerated dose of Glivec® in combination with mFOLFOX-Avastin®. Patients will be enrolled into each dose level in 3 patient cohorts. Additional cohorts will be enrolled, or dose levels opened, subject to the toxicities observed. Once the MTD has been determined the dose level below will be re-opened and extra patients, to a total of 15, will be enrolled.

NCT ID: NCT00952016 Terminated - Clinical trials for Advanced Colorectal Cancer

Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency

MESH
Start date: February 2009
Phase: Phase 2
Study type: Interventional

To assess the efficacy of methotrexate in a genetically selected population of patients with advanced colorectal cancer, who have loss of a particular gene, MSH2. The efficacy of methotrexate will be evaluated by the proportion of cases that have a significant response to treatment (objective response rate).

NCT ID: NCT00824161 Terminated - Clinical trials for Advanced Colorectal Cancer

Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall survival, and the safety profile of TAS-109